Emerging Technologies in Drug Discovery and Development

Shanghai, September 17-19, 2024.

Weikang Tao, CEO of Shanghai Hengrui Pharmaceutical Co.,TLD., R&D center and VP of Hengrui Medicine, China

Chang Bai, VP of Shanghai Hengrui Pharmaceutical Co.,TLD., R&D center, China

Feng He, VP of Shanghai Hengrui Pharmaceutical Co.,TLD., R&D center, China

Dafang Zhong, Director of Drug metabolism, Shanghai Institute of Pharmaceuticals, Chinese Academy of Sciences, China

Johan Gabrielsson, Professor of integrative pharmacology, Uppsala, Sweden

Emre Isin, Director, Head of Biotransformation and Enzymology, UCB Biopharma, Belgium

Zeping Hu, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China

Jiuming He, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, China

Xuanjia Peng, Head of DEL (DNA-Encoded Library), WuXi AppTec, China

Jie Wang, Site Director of Hengrui Nanjing Research Institute, China

Jingwu Kang, The state key laboratory for bioorganic chemistry, Shanghai institute of organic chemistry, Chinese academy of sciences, China

Hongming Chen, Principal Investigator of Guangzhou Regenerative Medicine and Health-Guangdong Laboratory (GRMH-GDL), China

Hui Ye, Associate Professor, State Key Laboratory of Natural Medicines, China Pharmaceutical University, China

Godefridus J. Peters, VU University Medical Center Amsterdam, The Netherlands

Alex Avdeef, CEO, In ADME Research, USA

Kiyohiko Sugano, Professor, Ritsumeikan University, Japan

Klara Valko, CEO, Biomimetic chromatography Ltd., UK

Rolf Hilfiker, Head of the Department Solid-State Development, Solvias AG, Switzerland

Hongcan Ren, Principal Scientist of Hutchison Medipharma Ltd., China

Xiaoqiang Xiang, Assoc. Prof , Acting director of Dept. of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, China

Yang LuAssoc. Prof , Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, China

Kin Tam, Assoc. Prof, Faculty of Health Sciences, University of Macau, Chief Editor of ADMET & DMPK, Macau

Yong-Moon Lee, Chungbuk National University, Republic of Korea

Hong Zhuang, Sr. Director of Turning Point Therapeutics, USA

Hua Lv, Clinical Pharmacology Director, Jiangsu Hengri Medicine CO., TLD., China

Jiaan Yang, CEO, Shanghai Micro Pharmatech, China

Xi Zhu, Director of Shanghai INNOSTAR Co., Ltd, China

Guocai Lu, CEO of CTI Biotechnology (Suzhou) Co., Ltd, China

Xiaobo Cen, CEO of West China-Frontier PharmaTech Co., Ltd, China

Xing Sun, Director of Shanghai Shengdi, China

Henry Li, CSO of Crown Bioscience (Taicang) Inc., China

Henry Kwok, Assoc. Prof, Faculty of Health Sciences, University of Macau, Macau

Ying Fu, Professor, Applied electromagnetics, School of Information Technology, Halmstad University, Sweden Molecular Bioimaging

Zheming Gu, Gennral Manager of Value Pharmaceutical Services, China Metabolite profiling and mass balance

Jing Li, CSO of Eternity Bioscience Inc, affiliated with Jangsu Hengrui Medicine, USA Hit finding and Lead screening 

Mingyue Zheng, Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China Drug design and AI

Pingyan Bie, Senior Director of Medicinal Chemistry, Zhejiang Hisun Pharmaceutical Co. Ltd., China Drug discovery 

Bob Zhang, CEO, Kunming Biomed International (KBI), China Translational animal model

Ismael Zamora, CEO, Lead Molecular Design, S.L., and Associate Professor, Universitat Pompeu Fabra, Spain

Wouter Driessen, Principal scientist and DMPK/PD project leader, Roche Basel, Switzerland 

Duanyun Si, Excutive Director of State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, China

Christel Bergström, Professor, Uppsala University, Sweden

Kimiyoshi Ichida, Professor at the Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Japan

Fan Wu, Senior Principal Scientist at Bristol-Myers Squibb, USA

Sylvia Zhao, Executive Director, PK Sciences China/Japan Site Head, Novartis Institute of BioMedical Research (NIBR)

Sami Svanbäck, CEO, The Solubility Company, Finland

Yutai Li, Principal Scientist, Merck & Co., Safety assessment and laboratory animal resources, USA